

Akeso (9926 HK)

Key data readouts for AK112 to validate global potential

In 1H25, Akeso reported product sales of RMB1.4bn (+49% YoY), achieving 43% of our prior full-year estimate, largely in line with our expectations. The NRDL inclusions of 2L+ cervical cancer for AK104 and 2L+ EGFRm NSCLC for AK112 have contributed to the sales growth. Looking ahead to 2026, we anticipate additional NRDL inclusions for AK104 in 1L gastric cancer and 1L cervical cancer, and for AK112 in 1L PD-L1+ NSCLC, which should further accelerate product sales growth. Operationally, Akeso demonstrated improved cost efficiency in 1H25, with selling and R&D expenses as a percentage of product sales shrinking to 48% and 52%, respectively (from 51% and 58% in FY24). The Company reported an attributable net loss of RMB570mn in 1H25 (vs RMB239mn in 1H24), while maintaining a solid cash position as of 1H25 of RMB7.1bn.

■ **AK112 achieves OS significance in China HARMONi-A study, with global results upcoming.** In the final analysis of the China HARMONi-A Ph3 trial, Akeso announced AK112 achieved statistically significant OS benefit in 2L+ EGFRm NSCLC, following prior interim updates showing OS HRs of 0.80 (0.59–1.08) at 52% data maturity and 0.72 (0.48–1.09) at 30% maturity. Detailed results are expected to be presented at an upcoming conference. With 276 patients from the China trial included in the global HARMONi study, Summit previously reported an OS HR of 0.79 (0.62–1.01; $p=0.057$) of the study, missing statistical significance, which is required for a US BLA submission. Summit expects to release detailed data of the global HARMONi trial in the coming WCLC next month ([link](#)). With the China trial now positive for OS, we think the likelihood of the global trial achieving significance has improved, although we continue to view the primary value of AK112 in NSCLC overseas to lie in the frontline setting. Additionally, AK112 has met the PFS endpoint in a head-to-head 1L sqNSCLC trial versus tislelizumab + chemo, with full data expected to be disclosed shortly, potentially at ESMO meeting in October.

■ **AK104 advances toward global development.** Akeso is accelerating the global development of AK104, beyond 1L/2L+ CC and 1L GC. In China, AK104 is currently in multiple Ph3 trials for 2L and perioperative GC, multiple lines of HCC (adjuvant and mid-stage treatment), and NSCLC (1L PD-L1- and consolidation therapy). Notably, Akeso will start a global Ph2 registrational trial of AK104 + lenvatinib for IO-resistant 2L HCC, marking a significant step in the asset's global expansion. Akeso is also exploring AK104 in combo with AK112 in NSCLC, with encouraging preliminary results according to the mgmt. Furthermore, Akeso is further diversifying its pipeline with early-stage ADC programs, including HER3 ADC and Trop2/Nectin4 ADC currently in Ph1 trials. The Company plans to evaluate combinations of AK104 or AK112 with these ADCs.

■ **Maintain BUY.** With key data readouts expected at the upcoming WCLC and ESMO conferences, we look forward to further evidence supporting the translatability of Akeso's China clinical results to global settings as well as AK112's superiority over the current SoC. We also see the partnership potential for AK104. We raise our DCF-based TP from HK\$108.03 to HK\$182.12 (WACC: 8.37%, terminal growth rate: 4.5%).

Earnings Summary

(YE 31 Dec)	FY23A	FY24A	FY25E	FY26E	FY27E
Revenue (RMB mn)	4,526	2,124	3,181	5,021	8,449
YoY growth (%)	440.3	(53.1)	49.8	57.8	68.3
Net profit (RMB mn)	2,028.3	(501.1)	(862.8)	25.4	1,551.6
EPS (Reported) (RMB)	2.42	(0.59)	(0.96)	0.03	1.73
R&D expenses (RMB mn)	(1,254)	(1,188)	(1,462)	(1,720)	(1,957)

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

Target Price	HK\$182.12
(Previous TP)	HK\$108.03)
Up/Downside	16.0%
Current Price	HK\$157.00

China Healthcare

Jill WU, CFA

(852) 3900 0842

jillwu@cmbi.com.hk

Andy WANG

(852) 3657 6288

andywang@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	140,922.1
Avg 3 mths t/o (HK\$ mn)	1,487.1
52w High/Low (HK\$)	176.90/45.25
Total Issued Shares (mn)	897.6

Source: FactSet

Shareholding Structure

Yu Xia	12.1%
Baiyong Li	6.4%


Source: Bloomberg

Share Performance

	Absolute	Relative
1-mth	5.3%	6.1%
3-mth	87.4%	73.8%
6-mth	108.8%	96.5%

Source: FactSet

12-mth Price Performance



Source: FactSet

Figure 1: Risk-adjusted DCF valuation

DCF Valuation (RMB mn)	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	2035E
EBIT	-1,003	-85	1,807	2,739	4,434	6,512	8,727	10,820	11,619	12,250	12,161
Tax rate	0%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%
EBIT*(1-tax rate)	-1,003	-72	1,536	2,328	3,769	5,535	7,418	9,197	9,876	10,413	10,337
+ D&A	193	189	186	182	179	176	173	170	168	165	163
- Change in working capital	-123	-604	-234	-324	-351	-234	-139	3	33	154	227
- Capex	-200	-100	-100	-100	-100	-100	-100	-100	-100	-100	-100
FCFF	-1,133	-587	1,387	2,086	3,497	5,377	7,352	9,271	9,977	10,632	10,627
Terminal value											287,155
FCF + Terminal value	-1,003	-85	1,807	2,739	4,434	6,512	8,727	10,820	11,619	12,250	12,161
Present value of enterprise (RMB mn)	148,412										
Net debt (RMB mn)	-1,923										
Non-controlling interests (RMB mn)	-60										
Equity value (RMB mn)	150,396										
No. of shares (mn)	898										
DCF per shares (RMB)	167.55										
DCF per shares (HK\$)	182.12										
Terminal growth rate	4.5%										
WACC	8.37%										
Cost of Equity	11.5%										
Cost of Debt	3.0%										
Equity Beta	0.9										
Risk Free Rate	2.5%										
Market Risk Premium	10.0%										
Target Debt to Asset ratio	35.0%										
Effective Corporate Tax Rate	15.0%										

Source: CMBIGM estimates

Figure 2: Sensitivity analysis (HK\$)

Terminal growth rate	WACC				
	7.37%	7.87%	8.37%	8.87%	9.37%
5.5%	373.96	289.17	234.08	195.46	166.92
5.0%	302.47	244.72	204.25	174.34	151.36
4.5%	255.91	213.48	182.12	158.05	139.00
4.0%	223.18	190.31	165.07	145.10	128.94
3.5%	198.91	172.44	151.52	134.57	120.60

Source: CMBIGM estimates

Figure 3: CMBIGM estimates revision

RMB mn	New			Old			Diff (%)		
	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Revenue	3,181	5,021	8,449	3,385	5,072	8,110	-6%	-1%	4%
Gross profit	2,559	4,087	7,094	2,762	4,175	6,891	-7%	-2%	3%
Operating profit	-1,003	-85	1,807	-296	411	1,937	N/A	N/A	-7%
Net profit	-863	25	1,552	-192	414	1,684	N/A	-94%	-8%
EPS (RMB)	(0.96)	0.03	1.73	(0.21)	0.46	1.88	N/A	-94%	-8%
Gross margin	80.45%	81.41%	83.97%	81.59%	82.33%	84.96%	-1.14 ppt	-0.92 ppt	-1.00 ppt

Source: Company data, CMBIGM estimates

Figure 4: CMBIGM estimates vs consensus

RMB mn	CMBIGM			Consensus			Diff (%)		
	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Revenue	3,181	5,021	8,449	3,496	5,466	8,053	-9%	-8%	5%
Gross profit	2,559	4,087	7,094	3,073	4,827	7,166	-17%	-15%	-1%
Operating profit	-1,003	-85	1,807	136	1,092	2,545	N/A	N/A	-29%
Net profit	-863	25	1,552	37	826	2,072	N/A	-97%	-25%
EPS (RMB)	(0.96)	0.03	1.73	0.04	0.94	2.36	N/A	-97%	-27%
Gross margin	80.45%	81.41%	83.97%	87.91%	88.31%	88.98%	-7.46 ppt	-6.90 ppt	-5.01 ppt

Source: Company data, Bloomberg, CMBIGM estimates

Financial Summary

INCOME STATEMENT	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec (RMB mn)						
Revenue	838	4,526	2,124	3,181	5,021	8,449
Cost of goods sold	(94)	(133)	(289)	(622)	(934)	(1,355)
Gross profit	744	4,393	1,835	2,559	4,087	7,094
Operating expenses	(2,122)	(2,363)	(2,268)	(3,264)	(3,937)	(5,101)
Selling expense	(553)	(890)	(1,002)	(1,399)	(1,892)	(2,549)
Admin expense	(199)	(200)	(204)	(300)	(460)	(682)
R&D expense	(1,323)	(1,254)	(1,188)	(1,462)	(1,720)	(1,957)
Others	(48)	(19)	125	(102)	134	86
Operating profit	(1,406)	1,862	(618)	(1,003)	(85)	1,807
Net Interest income/(expense)	(43)	(87)	(68)	(158)	(119)	(119)
Pre-tax profit	(1,422)	1,943	(501)	(863)	31	1,875
Income tax	0	(0)	0	0	(5)	(281)
After tax profit	(1,422)	1,942	(501)	(863)	26	1,593
Minority interest	(254)	(86)	0	0	1	42
Net profit	(1,168)	2,028	(501)	(863)	25	1,552

BALANCE SHEET	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec (RMB mn)						
Current assets	3,058	5,677	8,692	7,895	7,749	9,206
Cash & equivalents	2,092	1,542	6,918	5,875	5,336	6,421
Account receivables	271	296	525	637	992	1,524
Inventories	342	392	707	841	879	718
Prepayment	157	95	116	116	116	116
Financial assets at FVTPL	196	852	426	426	426	426
Other current assets	0	2,500	0	0	0	0
Non-current assets	2,437	3,211	3,665	3,672	3,583	3,497
PP&E	2,000	2,824	3,231	3,257	3,187	3,120
Right-of-use assets	163	338	320	300	281	262
Intangibles	8	6	12	12	12	12
Financial assets at FVTPL	10	12	16	16	16	16
Other non-current assets	256	30	87	87	87	87
Total assets	5,496	8,888	12,356	11,567	11,331	12,703
Current liabilities	1,361	1,205	1,687	1,760	1,498	1,586
Short-term borrowings	446	391	535	535	535	535
Account payables	309	355	425	498	237	325
Other current liabilities	600	445	716	716	716	716
Lease liabilities	6	15	10	10	10	10
Non-current liabilities	1,587	2,826	3,697	3,697	3,697	3,697
Long-term borrowings	1,421	2,577	3,406	3,406	3,406	3,406
Deferred income	160	240	290	290	290	290
Other non-current liabilities	6	9	1	1	1	1
Total liabilities	2,948	4,030	5,384	5,457	5,195	5,283
Share capital	0	0	0	0	0	0
Other reserves	2,636	4,692	6,814	5,951	5,977	7,218
Total shareholders equity	2,636	4,692	6,814	5,951	5,977	7,218
Minority interest	(88)	(174)	(60)	(60)	(59)	(18)
Total equity and liabilities	5,496	8,888	12,356	11,567	11,331	12,703

CASH FLOW	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec (RMB mn)						
Operating						
Profit before taxation	(1,422)	1,943	(501)	(863)	31	1,875
Depreciation & amortization	106	143	194	193	189	186
Tax paid	0	0	0	0	(5)	(281)
Change in working capital	60	418	(200)	(123)	(604)	(234)
Others	16	(36)	(20)	108	69	69
Net cash from operations	(1,240)	2,468	(528)	(685)	(320)	1,613
Investing						
Capital expenditure	(776)	(719)	(586)	(200)	(100)	(100)
Net proceeds from disposal of short-term investments	(200)	(3,055)	(1,024)	0	0	0
Others	86	(223)	87	0	0	0
Net cash from investing	(890)	(3,997)	(1,523)	(200)	(100)	(100)
Financing						
Dividend paid	0	0	0	0	0	(310)
Net borrowings	1,005	1,099	962	0	0	0
Proceeds from share issues	495	(3)	2,823	0	0	0
Share repurchases	0	0	0	0	0	0
Others	(15)	(135)	(396)	(158)	(119)	(119)
Net cash from financing	1,486	961	3,389	(158)	(119)	(429)
Net change in cash						
Cash at the beginning of the year	2,642	2,092	1,542	6,918	5,875	5,336
Exchange difference	95	19	35	0	0	0
Cash at the end of the year	2,092	1,542	6,918	5,875	5,336	6,421
GROWTH	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec						
Revenue	271.3%	440.3%	(53.1%)	49.8%	57.8%	68.3%
Gross profit	282.5%	490.8%	(58.2%)	39.5%	59.7%	73.6%
Net profit	na	na	na	na	na	6,001.2%
PROFITABILITY	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec						
Gross profit margin	88.8%	97.1%	86.4%	80.5%	81.4%	84.0%
Operating margin	(167.9%)	41.1%	(29.1%)	(31.5%)	(1.7%)	21.4%
Return on equity (ROE)	(40.3%)	55.4%	(8.7%)	(13.5%)	0.4%	23.5%
GEARING/LIQUIDITY/ACTIVITIES	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec						
Current ratio (x)	2.2	4.7	5.2	4.5	5.2	5.8
VALUATION	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec						
P/E	ns	59.6	ns	ns	5,092.4	83.5
P/B	46.7	26.7	18.2	22.0	21.9	18.0

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report. Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months
NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.